Comment on

• Prospective comparison of the immune response of infants to three Haemophilus influenzae type b vaccines.

  Turner RB, Cimino CO, Sullivan BJ. Turner RB, et al. Pediatr Infect Dis J. 1991 Feb;10(2):108-12. doi: 10.1097/00006454-199102000-00006. Pediatr Infect Dis J. 1991. PMID: 2062600
• Safety and immunogenicity of a Haemophilus influenzae type b conjugate vaccine in a high risk American Indian population.

  Santosham M, Hill J, Wolff M, Reid R, Lukacs L, Ahonkhai V. Santosham M, et al. Pediatr Infect Dis J. 1991 Feb;10(2):113-7. doi: 10.1097/00006454-199102000-00007. Pediatr Infect Dis J. 1991. PMID: 2062601
• Safety and immunogenicity of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in infancy. The Northern California Kaiser Permanente Vaccine Study Center Pediatrics Group.

  Black SB, Shinefield HR, Lampert D, Fireman B, Hiatt RA, Polen M, Vittinghoff E. Black SB, et al. Pediatr Infect Dis J. 1991 Feb;10(2):92-6. doi: 10.1097/00006454-199102000-00003. Pediatr Infect Dis J. 1991. PMID: 2062620 Clinical Trial.
• Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in a United States population of 61,080 children. The Northern California Kaiser Permanente Vaccine Study Center Pediatrics Group.

  Black SB, Shinefield HR, Fireman B, Hiatt R, Polen M, Vittinghoff E. Black SB, et al. Pediatr Infect Dis J. 1991 Feb;10(2):97-104. doi: 10.1097/00006454-199102000-00004. Pediatr Infect Dis J. 1991. PMID: 2062621 Clinical Trial.